Biotech Achillion Pharmaceuticals is working to get its name on the short list of blockbuster hepatitis C contenders, revealing promising Phase II data for a combination of its antiviral with Gilead Sciences' leading Sovaldi.
The latest batch of Israeli biotechs to hit Nasdaq hasn't been doing so well. But that hasn't deterred Foamix Pharmaceuticals from joining the tail end of the big biotech rush into the public markets.
Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.
Amid its fight to stave off a hostile takeover, Botox maker Allergan is making a buy of its own, trading up to $587.5 million for a midstage bladder drug from the biotech Taris.
AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.
In this week's EuroBiotech Report, a court convicted NeuroSearch of stock price manipulation and imposed a fine of DKK 5 million ($0.9 million) more than four years after NeuroSearch published the clinical trial results--and subsequent reappraisal--that caused its stock to surge and slump. And more.
A year after enduring a stinging FDA rejection, Merck has convinced the agency to sign off on lower doses of its suvorexant, a novel sleep drug once predicted to become a blockbuster.
InterMune's promising treatment for a rare lung disease has put it in Big Pharma's crosshairs, according to a report, news that sent the biotech's shares soaring as much as 20% on Wednesday.
Philadelphia's Tarsa Therapeutics has nailed down a $10 million credit facility to help bankroll an FDA submission for Ostora, the company's treatment for postmenopausal osteoporosis.
San Diego's Otonomy pulled off a $100 million Wall Street debut, lining its pockets as it works to get a late-stage ear treatment through the FDA and onto the market.
Rigel Pharmaceuticals' just got a little thinner, as another failed clinical trial has dimmed its hopes in dry eye disease, the latest in a string of missteps for the biotech.
Merck KGaA is talking up deals again, pointing to its healthy cash reserves and saying it can well afford a blockbuster buyout to bolster its pipeline. But that's been the story for nearly a year, so what's the German giant waiting on?
AstraZeneca had some upbeat news to report Wednesday morning, noting that a slate of key Phase III combination studies for the gout drug lesinurad crossed the finish line with positive results for three out of four primary endpoints, raising hopes that the once star-crossed pharma giant may be on the verge of a blockbuster approval. And the company says it plans to push ahead with regulatory applications with the late-stage data now in hand.
South Korea's Celltrion is aiming to be second in line when biosimilars make their U.S. landfall, filing an FDA application to market a knockoff of Johnson & Johnson's blockbuster Remicade.
Prosensa, one of a handful of biotechs racing to develop treatments for Duchenne muscular dystrophy, has secured $7 million from a nonprofit to accelerate its R&D efforts.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
Cambridge, MA's Tokai Pharmaceuticals is joining the IPO queue with eyes on $75 million, cash that would get its triple-threat prostate cancer treatment into Phase III trials.
Knight Therapeutics intends to find out how much drugmakers are willing to pay for the FDA's attention, putting its priority review voucher up for sale and shining a light on a program designed to encourage neglected disease R&D.
Still riding high on some strong early-year data for its liver disease treatment, Intercept Pharmaceuticals' shares shot up once more as its lead drug came through in Phase IIb, dismissing some earlier safety worries and setting the table for late-stage study.
After making international headlines with the West's first approval for a gene therapy, pioneering biotech uniQure is working to flesh out its pipeline of one-time treatments, buying into an early-stage shot at heart failure that could put its technology on the biggest stage yet.